Bloomberg News recently reported that French health authorities are planning on suspending the sales of Bayer AG Diane-35 acne treatment. This drug, commonly used as a contraceptive, can increase the risk of blood clots.
Various sources have reported that this drug has led to four fatalities over the past 25 years. After a review of the treatment’s risks and benefits, the drug was found to be unfavorable. In a recent press conference, it was noted that this drug provides an unnecessary risk to women who use it as a contraceptive.
Dr. Joel Schlessinger explains how this could affect the United States use of contraceptives.
“France suspending sale of acne treatment is topical in that, while this treatment is not available in the U.S., there are other drugs that have similar effects,” said Dr. Joel Schlessinger. “Diane-35 is closest to Yaz and Yazmin, two oral contraceptives that we frequently see used for acne in young women.”
The suspension of Diane-35 will take effect in three months. This drug has not been approved for use in the United States.
Dr. Joel Schlessinger believes the ban of similar drugs may be coming soon.
“This may eventually happen in the United States as these medications have been associated with blood clots and other issues in women,” said Dr. Joel Schlessinger.
“We recommend that anyone on these should be carefully screened for any clotting issues before using them.”
Learn more about other pharmaceutical drugs from Dr. Joel Schlessinger.
A new form of Accutane is now available in the United States to treat recalcitrant nodular acne. Dr. Joel Schlessinger is excited about this effective treatment – learn more about it here.
Dr. Joel Schlessinger recently commented on the outbreak of bed bugs across the United States and the new drugs that can be used to treat them. Read more of Dr. Joel Schlessinger’s commentary on bed bugs here.
Do you have a question about a pharmaceutical drug? Ask your questions in the comments.